Watch for the Q4 2026 end-of-Phase 1 meeting with FDA for BH-30643, which could define an accelerated approval pathway and be a major catalyst. The IPO cash removes near-term dilution risk, but the stock's valuation hinges on clinical data readouts, not current earnings.
Price Chart
Executive Summary
BlossomHill Therapeutics reported Q2 2026 net loss of $23.8M ($-8.75/share), far exceeding the consensus estimate of $-0.77, driven by increased R&D and G&A expenses. The company highlighted FDA Fast Track designation for BH-30643 and a successful $168.3M IPO in August, extending its cash runway into Q2 2028. The massive EPS miss reflects early-stage clinical spending, not operational deterioration, and the stock's prior strong returns suggest the market is focused on pipeline catalysts rather than current losses.
Key Financial Metrics
Key Facts
- Q2 2026 net loss of $23.8M vs $13.2M in Q2 2025
- EPS of $-8.75 vs consensus $-0.77 (1036% miss)
- R&D expenses $21.4M, up 71% YoY due to SOLARA trial and IND-enabling studies
- Cash and equivalents $95.4M at June 30, 2026; IPO added $168.3M gross proceeds in August
- FDA Fast Track designation granted for BH-30643 in EGFR C797S-positive NSCLC
- BH-30643 showed 45% ORR and 88% DCR in C797S resistance patients
- End-of-Phase 1 meeting with FDA for BH-30643 expected Q4 2026
Financial Impact
Net loss widened to $23.8M from $13.2M; cash runway extended into Q2 2028 with IPO proceeds
Risk Factors
- Clinical-stage biotech with no approved products or revenue; net losses will continue to widen
- BH-30643 pivotal trial success and regulatory pathway are binary events with high uncertainty
- Competition from other EGFR inhibitors and novel therapies in NSCLC
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3364633 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 28, 2026 29d ago | Press Release | $21.34 $16.39 | ▲ +23.20% | ▲ +23.16% | $16.50 (+22.68%) |
Sep 18, 2026 5w ago | 8-K | $25.74 $13.94 | ▲ +45.84% | ▲ +46.05% | $16.50 (+35.90%) |
Sep 18, 2026 5w ago | Press Release | $25.74 $13.94 | ▼ −45.84% | ▼ −46.05% | $16.50 (−35.90%) |
Sep 15, 2026 6w ago | 8-K | $22.17 $15.48 | ▼ −30.18% | ▼ −33.15% | $16.50 (−25.58%) |
Aug 12, 2026 10w ago | Insider Cluster | $16.35 $20.86 | ▲ +27.58% | ▲ +29.33% | $16.50 (+0.92%) |
Aug 10, 2026 11w ago | Insider Cluster | $16.52 $22.00 | ▲ +33.17% | ▲ +34.23% | $16.50 (−0.12%) |
Aug 10, 2026 11w ago | 8-K | $16.52 $22.00 | ▲ +33.17% | ▲ +34.23% | $16.50 (−0.12%) |
Aug 7, 2026 11w ago | 424B4 | $15.99 $22.93 | ▲ +43.40% | ▲ +44.32% | $16.50 (+3.19%) |
Aug 7, 2026 11w ago | EFFECT | $16.00 $22.01 | ▲ +37.56% | ▲ +37.96% | $16.50 (+3.13%) |
Aug 6, 2026 11w ago | 3 | $16.00 $22.01 | ▲ +37.56% | ▲ +37.96% | $16.50 (+3.13%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers